About us

Our research program employs functionalized nanomaterials in medicine. We are a part of the Department of Biomedical Engineering. Our expertise is in the development of animal models of cancer, kidney disease and metals-related diseases, and in the development of engineered nanomaterials to diagnose, prevent and treat such diseases.

News

October, 2021

Yantasee and team have received the USPTO’s Notice of Allowance for two US patents including  US 16/999,948 titled “Immunotherapeutic constructs and methods of their use” and US 17/023,311 titled “Therapeutic constructs for co-delivery of mitotic kinase inhibitor and immune checkpoint inhibitor”. The patent should be issued shortly. Both technologies are joint inventions of OHSU and her startup, PDX Pharmaceuticals, Inc. 

September, 2021

Yantasee Lab in collaboration with PDX Pharmaceuticals, Inc., has received a perfect score (10) on its fast track SBIR grant application to the NCI. The application focuses on development of PDX Pharma’s ARACTM pipeline, a systemic nano-immunotherapy for tumor not accessible for local treatment or injection. Grant title: Novel Nano-immunotherapy for Treatment of Non-small Cell Lung Cancer, and was awarded $2.26 M ($378K as phase I) over 3 years.

Furthermore, the team scored very high (18) on its direct phase II SBIR grant application to the NCI. The application focuses on IND enabling studies of AIRISETM pipeline, an innovative, next generation immunotherapeutic. Grant title: In Situ Tumor Vaccination with a Nano-oligo Therapeutic to Induce Whole-body Antitumor Immune Response, and was awarded $2.0 M over 1.5 years

July 29, 2021

Yantasee Lab in collaboration with PDX Pharmaceuticals, Inc. and the Knight Cancer Institute recently published a paper in the Advanced Materials Journal on in situ tumor vaccination with AIRISE-02. This paper was featured as a cover article in Advanced Materials (impact factor 30.8), and selected for women in materials science collection. To read the paper, click here. To read more about the Women in Materials Science collection, click here

May 6, 2021

Yantasee Lab in collaboration with PDX Pharmaceuticals, Inc., has received the USPTO’s Notice of Allowance for the patent application US 15/429,971 on its core nanoparticle technology (Pdx-NP) encompassing “Compositions” and “Method of Use” claims. The patent should be issued shortly. The technology is a joint invention of OHSU and PDX Pharma. It was first reported as a cover article in Advanced Functional Materials in 2015.

About Dr. Yantasee

In addition to her position as Professor at OHSU, Dr. Yantasee is also a Research Member of the Knight Cancer Institute and a Nanomedicine Signature Researcher at Oregon Nanoscience and Microtechnologies Institute (ONAMI).